D-0147-2020 Class II Terminated

Recalled by Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center — West Columbia, SC

FDA drug recall D-0147-2020 was initiated by Nephron Pharmaceuticals Corporation Dba Nephron Sterile Compounding Center on Oct 9, 2019 and is designated Class II. Reason for recall: GMP Deviations: potential glass contamination The recall status is terminated (terminated Dec 1, 2020). Affected quantity: 1855 bags.

Recall details

Product Type
Drugs
Report Date
Oct 30, 2019
Initiation Date
Oct 9, 2019
Termination Date
Dec 1, 2020
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1855 bags

Product description

PF-Fentanyl Citrate (2 mcg/mL)* & Bupivacaine HCl 0.0625 in 0.9% Sodium Chloride Injection-250 mL Total Dose: (500 mcg/156.3 mg)/250 mL, Rx Only, Nephron 503B Outsourcing Facility 4500 12th St. Extension West Columbia, SC 29172 NDC 69374-0525-25

Reason for recall

GMP Deviations: potential glass contamination

Distribution pattern

Nationwide.

Code information

Lots: FB9001 A Exp. 10/31/2019, FB9001B Exp. 10/31/2019; FB9013A Exp. 12/08/2019; FB9015A Exp. 12/14/2019

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0147-2020
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0147-2020. Report a data issue: hello@regdatalab.com.